TCM
FATE icon

Tygh Capital Management’s Fate Therapeutics FATE Stock Holding History

Tygh Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$2.85M Sell
48,675
-98
-0.2% -$5.55K 0.36% 74
2021
Q3 		$2.89M Buy
48,773
+12,358
+34% +$969K 0.39% 80
2021
Q2 		$3.16M Sell
36,415
-388
-1% -$31.3K 0.43% 79
2021
Q1 		$3.03M Buy
36,803
+1,467
+4% +$141K 0.43% 79
2020
Q4 		$3.21M Buy
+35,336
New +$2.19M 0.5% 76

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tygh Capital Management's FATE Position: Q4 2021 in Review

Tygh Capital Management reduced its Fate Therapeutics (FATE) stake by 0.2% in Q4 2021, selling an estimated $5.55K and leaving 48,675 shares worth $2.85M. The position accounts for 0.36% of the portfolio, ranked #74.

Tygh Capital Management first reported a position in FATE in Q4 2020 and has held it in 5 quarters since. The position peaked at $3.21M in Q4 2020. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

  • Tygh Capital Management held 48,675 shares of Fate Therapeutics worth $2.85M as of Q4 2021.
  • Tygh Capital Management sold 98 Fate Therapeutics shares in Q4 2021, an estimated $5.55K.
  • Fate Therapeutics made up 0.36% of Tygh Capital Management's portfolio in Q4 2021, its #74 holding.
  • Tygh Capital Management first reported a position in Fate Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • Tygh Capital Management's Fate Therapeutics position peaked at $3.21M in Q4 2020.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Tygh Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.